EMA Authorised: Enspryng (satralizumab) — Roche Registration GmbH

View source ↗

Summary

The EU authorised Enspryng (satralizumab) by Roche Registration GmbH for neuromyelitis optica spectrum disorder (orphan medicine).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica Spectrum Disorder

Drugs mentioned

• Enspryng (satralizumab)

Snippet

Status: Authorised. Therapeutic area: Neuromyelitis Optica. MAH: Roche Registration GmbH. Decision date: 10/02/2026. Orphan medicine